
Sign up to save your podcasts
Or


This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.
By Sam and Karine4.8
193193 ratings
This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.

317 Listeners

504 Listeners

40 Listeners

121 Listeners

58 Listeners

3,364 Listeners

1,152 Listeners

187 Listeners

46 Listeners

516 Listeners

376 Listeners

52 Listeners

60 Listeners

51 Listeners

47 Listeners